Convatec Group PLC
CTEC
Company Profile
Business description
Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 32% and 28% of total revenue, respectively. Continence care has become a slightly smaller business (22% of revenue) following the decision to exit the acute care market, and infusion sets contribute 18% of consolidated revenue.
Contact
20 Eastbourne Terrace
7th Floor
Paddington
LondonW2 6LG
GBRT: +44 7826447807
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2026
Employees
10,000
Stocks News & Analysis
stocks
What AI means for US software companies’ moats
We’re no longer certain that software firms will outperform over the next decade, but positive outcomes remain possible for names like Salesforce.
stocks
Lower moat ratings on four ASX shares due to AI
We believe AI weakens the competitive advantage of these companies.
stocks
What Q4 US earnings did and didn’t tell us about AI and the outlook for tech shares
Tech saw solid earnings, but there are more questions around which companies will benefit from AI, and which will be hurt.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,823.60 | 16.90 | -0.19% |
| CAC 40 | 7,818.53 | 174.96 | -2.19% |
| DAX 40 | 23,153.99 | 437.04 | -1.85% |
| Dow JONES (US) | 46,642.72 | 858.83 | -1.81% |
| FTSE 100 | 10,147.21 | 137.54 | -1.34% |
| HKSE | 25,408.46 | 348.83 | -1.35% |
| NASDAQ | 22,090.37 | 297.31 | -1.33% |
| Nikkei 225 | 52,728.72 | 2,892.12 | -5.20% |
| NZX 50 Index | 13,098.83 | 519.06 | -3.81% |
| S&P 500 | 6,639.14 | 100.88 | -1.50% |
| S&P/ASX 200 | 8,599.00 | 3.30 | -0.04% |
| SSE Composite Index | 4,096.60 | 27.59 | -0.67% |